Mark Germain

Mark Germain is a managing director at Aentib Group. Mark has:

• been co-founder, director, chairman of the board and/or investor in over twenty companies in the biotech field
• assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions.

Prior to Aentib Mark co-founded numerous bio-technology companies, which have an aggregate market capitalization in excess of over $50 billion today and include Alexion (ALXN), Ariad (ARIA), Incyte (INCY), Neurocrine (NBIX), Pluristem (PSTI), Cell Therapeutics (CTIC), ChromaDex (CDXC), and others. He was also a senior advisor to a private enterprise in China recently sold to a major pharmaceutical company. Finally, Mark was actively involved in the formation of companies:

• recruiting management
• securing financing
• initiating and negotiating corporate partnerships
• licensing technology
• executing M&As
• creating and implementing strategic plans.

Mark graduated from New York University School of Law, Order of the Coif (top 5%), and was a partner in a New York law firm practicing corporate and securities law.